Gedatolisib

Drug Profile

Gedatolisib

Alternative Names: PF-05212384; PF-5212384; PKI-587

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Curie Institute; Eastchester Center for Cancer Care; Netherlands Cancer Institute; Pfizer; University of Florida
  • Class Antineoplastics; Morpholines; Piperidines; Small molecules; Triazines; Urea compounds
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 18 May 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT02920450)
  • 28 Feb 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03065062)
  • 28 Feb 2017 Pfizer plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT03065062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top